Fundação Butantan

What Fundação Butantan does

Fundação Butantan is a non-profit private foundation established in 1989 to support Instituto Butantan, a São Paulo state government biological research and manufacturing entity. It is the largest immunobiological producer in Latin America, manufacturing vaccines, antivenoms, and monoclonal antibodies through its Bioindustrial Center and a broader workforce of 1,001-5,000 employees, including 1,100 dedicated to production units. Its product portfolio includes trivalent influenza vaccine (80 million doses annually, supplying 100% of Brazil's public-sector demand), recombinant hepatitis B, HPV quadrivalent, rabies, and DTP/DTaP vaccines, plus 12 antivenoms. The foundation is the only producer of a fully Brazilian recombinant hepatitis B vaccine and operates four technology platforms: embryonated chicken eggs, VERO cell lines, Pichia angusta, and Saccharomyces cerevisiae. Pipeline assets include Butantan-DV dengue (Phase 3), chikungunya (Phase 3, technology licensed from Valneva), H7N9 pandemic candidate (WHO reference laboratory), and tetravalent influenza.

The foundation's revenue model is single-channel: all output is procured by the Brazilian Ministry of Health and distributed free of charge through the National Immunization Program (PNI). There is no direct B2B sales force, no commercial pricing to private payers, and no disclosed revenue figures. The foundation's commercial diversification runs through partnerships rather than direct sales: WuXi Vaccines (commercial manufacturing for international markets), Valneva (chikungunya technology transfer), Sandoz (adalimumab biosimilar PDP), NIH and ATCC (dengue R&D), FAPESP/GSK (research alliance), and WHO (H7N9 pandemic preparedness). Business model is effectively a public-sector contract manufacturer and technology licensor, with growth driven by pipeline expansion, regulatory certifications (ANVISA GMP, EU QP audit, WHO prequalification), and export-oriented manufacturing partnerships rather than price or volume increases on the existing PNI contract.

Name

Fundação Butantan

Legal name

Fundação Butantan

Website

https://fundacaobutantan.org.br

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Fundação Butantan is a non-profit foundation supporting Instituto Butantan and operating Latin America's largest immunobiological manufacturer, producing vaccines, antivenoms, and monoclonal antibodies exclusively for the Brazilian Ministry of Health's National Immunization Program.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing

akta.pro primary industry

Travel & Tropical Disease Vaccines (HLAIAEAE)

akta.pro secondary industries

Funding, Reimbursement & Vaccines-for-Children (VFC)/Public Purchase Programs (HLAJAHAK), Immunization & Vaccine Delivery Programs (BPADAIAB)

Keywords

• Vaccine manufacturing
• Antivenom production
• Biopharmaceutical products
• Public health biologics
• Monoclonal antibody development

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Vaccine and Immunobiological Sales: Primary revenue stream from sale of vaccines, serums, and monoclonal antibodies to the Brazilian Ministry of Health through the National Immunization Program (PNI). Products are supplied free of charge to the population under public health programs.
2. Productive Development Partnerships (PDPs): Partnerships for technology transfer and co-production with external laboratories including pharmaceutical companies for production of biologicals like adalimumab.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Fundação Butantan is a Brazilian non-profit foundation that manufactures and supplies immunobiological products, including vaccines, antivenoms (soros), and monoclonal antibodies. Its products are delivered to the Brazilian Ministry of Health for distribution through the National Immunization Program (PNI), making it the largest producer of immunobiologicals in Latin America and the sole supplier of Brazil's influenza vaccine.

Product overview

Fundação Butantan is Brazil's largest immunobiological producer in Latin America, operating a comprehensive portfolio of vaccines and antivenoms supplied to the National Immunization Program (PNI). The vaccine portfolio includes: trivalent influenza vaccine (supplying 100% of Brazil's annual 80 million doses), inactivated rabies vaccine (VERO cell-based), inactivated hepatitis A vaccine, hepatitis B recombinant vaccine (only fully Brazilian-made recombinant vaccine), DTP, DTaP, and quadrivalent HPV vaccine. Pipeline products in development include the tetravalent attenuated dengue vaccine (Butantan-DV) with ANVISA GMP certification secured, H7N9 influenza vaccine (Phase II), chikungunya vaccine (Phase 3), tetravalent influenza vaccine, and Pertussis Low vaccine. The antivenom portfolio comprises 12 products including pentavalent antibothropic, anticrotalic, antielapid, anti-scorpion, anti-arachnid, antilonomic serums, and antidiphtheria, antitetanic, antibotulinum, and antirabies antitoxins. Monoclonal antibody offerings include adalimumab produced under PDP with Sandoz.

Differentiator

Problem solved

Functional benefit

Products and services

• Trivalente Influenza Vaccine
• Vacina da Raiva (Rabies Vaccine)
• Vacina Hepatite A
• Vacina DTP
• Vacina Hepatite B (recombinante)
• Vacina DTaP
• Vacina HPV Quadrivalente
• Antivenoms (Soros Antiofídicos)
• Antidiphtheric Serum (Soro Antidiftérico)
• Antitetanic Serum (Soro Antitetânico)
• Anti-botulinum Serum AB (Soro Antibotulínico AB)
• Anti-rabies Serum (Soro Antirrábico)
• Adalimumab (Monoclonal Antibody)

Quantifiable outcome

• 80 million doses of influenza vaccine distributed annually (100% of Brazil's supply)
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core.

• WuXi VaccinescoreStrategic or Co-development Partner · 26 May 2026WuXi Vaccines provides end-to-end manufacturing services for the Butantan-DV dengue vaccine under a commercial manufacturing agreement. WuXi's drug substance facility (MFG23) and drug product facility (DP17) in Suzhou, China received ANVISA GMP certification. The partnership aims to deliver millions of doses to Brazil.
• NIH (National Institutes of Health)coreStrategic or Co-development PartnerPartnership for development of the tetravalent live attenuated dengue vaccine (Butantan-DV). NIH provides genetically attenuated virus strains for protection against all four dengue virus types.
• ATCC (American Type Culture Collection)coreStrategic or Co-development PartnerPartnership for dengue vaccine development providing reference materials and cell lines.
• ValnevacoreStrategic or Co-development PartnerTechnology transfer partnership for Chikungunya vaccine. Valneva developed the attenuated vaccine and is transferring technology to Butantan for local production. Butantan is conducting Phase 3 clinical trials with adolescents in Brazil.
• Sandoz do BrasilcoreStrategic or Co-development PartnerProductive Development Partnership (PDP) for production of adalimumab, a medication used to treat chronic inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and psoriasis.
• FAPESP/GSK/IBUcoreStrategic or Co-development PartnerPartnership through the Center of Excellence in New Target Discovery (CENTD), a research collaboration between FAPESP, GSK, and Instituto Butantan for discovery and development of new therapeutic targets.
• WHO (World Health Organization)coreStrategic or Co-development PartnerButantan was chosen as one of the global laboratories to produce and supply H7N9 influenza vaccine as part of WHO's pandemic preparedness strategy.
• Strategic Alliance PartnerscoreStrategic or Co-development PartnerStrategic Alliance Agreement regulates the functioning between Instituto Butantan and Fundação Butantan. Contract of Alliance establishes governance and operational framework.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bio-Manguinhos (Fiocruz): Brazil's other major public-sector immunobiological producer under the Fiocruz umbrella, supplying vaccines and diagnostics to Brazil's Ministry of Health through the National Immunization Program. Closest direct peer given shared public-sector Brazilian vaccine manufacturing model.
• Valneva: Specialty vaccine developer focused on travel and tropical disease vaccines (chikungunya, Japanese encephalitis). Direct comparator given Butantan-DV vaccine partnership and overlapping travel/tropical vaccine focus.

Broad incumbents

• Sanofi Pasteur: Global vaccine leader within Sanofi, with established operations and a broad vaccine portfolio including influenza, travel, and pediatric vaccines. Comparable as a multinational competitor and supply partner operating in Brazil's immunization ecosystem.
• GSK Vaccines: Major multinational vaccine producer with deep Brazilian presence, co-developing new targets with Butantan via the FAPESP-GSK-IBU CENTD partnership. Overlapping portfolio across routine and travel vaccines.
• Merck (MSD) Vaccines: Large multinational vaccine manufacturer with established Brazilian operations and a broad portfolio including HPV, pediatric, and travel vaccines. Competes for PNI contracts and overlaps with Butantan's recombinant vaccine and HPV offerings.
• Pfizer Vaccines: Major multinational vaccine manufacturer with strong Brazilian commercial operations; Butantan's medical director previously worked at Pfizer. Overlap in respiratory and routine immunization portfolios targeting similar Brazilian public-sector buyers.
• Serum Institute of India: World's largest vaccine manufacturer by doses, supplying developing-market immunization programs at scale. Highly comparable on scale, low-cost vaccine manufacturing, and public-sector/government buyer model.

Emerging players

• Sinopharm / China National Biotec Group (CNBG): China's largest state-owned biologics and vaccine manufacturer, structurally analogous to Butantan as a public-sector producer at massive scale. Comparable on integrated R&D and large-scale government-aligned vaccine production.
• Bharat Biotech: Indian vaccine and bio-therapeutics manufacturer with strong emerging-market public-sector presence and a broad vaccine portfolio including rotavirus, typhoid, and COVID-19. Comparable on cost-competitive emerging-market vaccine supply model.

Others

• WuXi Biologics: Contract development and manufacturing organization (CDMO) providing end-to-end vaccine manufacturing services to Butantan for the dengue vaccine at its Suzhou facilities. Comparable as a biologics manufacturing partner enabling Butantan's commercial pipeline scale-up.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/fundacaobutantan

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fundação Butantan